Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.
Journal: Frontiers in immunology
Published: February 18, 2026
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
Journal: Future oncology (London, England)
Published: January 11, 2025
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 03, 2023
IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience.
Journal: The American journal of gastroenterology
Published: December 31, 2022
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 06, 2020
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Journal: Immunotherapy
Published: November 30, 2017
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Journal: Reviews on recent clinical trials
Published: December 17, 2015
Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells.
Journal: EBioMedicine
Published: July 28, 2015
Detection of circulating tumor cells by photoacoustic flowmetry.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 22, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026